Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
Date:11/8/2010

DA. VIVUS received a Complete Response Letter (CRL) from the FDA and is preparing a written response to address the FDA's requests for information included in the CRL. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of male sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction.

For more information about the company, please visit www.vivus.com.  

Note to Investors As previously announced, VIVUS will hold a conference call and an audio webcast to discuss the third quarter financial results today, November 8, 2010, beginning at 1:30 p.m. Pacific Time.  You can listen to this call by dialing 1-877-359-2916 and outside the U.S. 1-224-357-2386. A webcast replay will be available for 30 days and can be accessed at http://ir.vivus.com/.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of VIVUS' written response to the FDA's complete response letter; the FDA's interpretation of the data VIVUS submits relating to the teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and our sleep apnea study (OB-204); that we may be required to conduct additional clinical trials; our history of losses and variabl
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new ... expanding list of health conditions, drug developers have ... the administration process and increase the efficiency and ...
(Date:12/13/2014)... Dec. 12, 2014  Radiologists can transmit their ... to their referring physicians, electronic health records (EHR) ... selected technology.  That was the ... Corporation (ADS) at the recent Radiology Society of ... of radiology reports in this manner also helps ...
(Date:12/13/2014)... Dec 12, 2014 Mindray Medical International Limited ... manufacturer and marketer of medical devices worldwide, today announced ... shareholders held in Hong Kong ... Mindray shareholders voted to re-elect incumbent directors Li Xiting ... Mindray,s shareholders did not re-elect Peter Wan ...
Breaking Medicine Technology:Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the J.P. Morgan 29th Annual Healthcare Conference in San ...   Interested parties may access a live audio ... the BioMarin website, www.BMRN.com .  A replay of the ...
... CLINTON, N.J., Jan. 5, 2011 Ikaria, Inc. today ... has granted INOMAX® (nitric oxide) for inhalation an additional ...  The action extends exclusivity for INOMAX from January 2013 ... submitted from three clinical trials of INOMAX in pre-term ...
Cached Medicine Technology:BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference 2FDA Extends Marketing Exclusivity for INOMAX® 2FDA Extends Marketing Exclusivity for INOMAX® 3
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... the holiday party season fast approaching, a new study reveals ... DUI arrests have fewer drunk drivers on their roads. ... more vigilantly are better able to deter inebriated revelers from ... any new laws are being passed regarding drinking and driving," ...
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... Mass., July 29 - Boston Scientific Corporation (NYSE: BSX ... Katharine T. Bartlett and Bruce L. Byrnes as Directors. ... Pye Professor of Law at the Duke University School of Law, ... through a period of major strategic expansion. During Bartlett,s tenure ...
... , NEW ORLEANS, July 29 ... its pioneering spirit again by leading the way to making healthy alternatives ... , , Consumers in Tokyo will be the first ... the first store planned to open in 2010. Japan makes sense as ...
... BATESVILLE, Ind., July 29 Hillenbrand, Inc. (NYSE: HI ... Wednesday, Aug. 12, 2009. The full text of the release and ... www.HillenbrandInc.com . , , The company ... financial analysts the same day at 8 a.m. ET. During the ...
... EMERYVILLE, Calif., July 29 Bionovo, Inc. (Nasdaq: BNVI ... needs in women,s health and oncology, today announced that Dr. Mary ... President and CFO, will be presenting at the BMO Capital Markets ... Wednesday, August 5, 2009. The event will be held at the ...
... , SOUTH SAN FRANCISCO, Calif., July 29 ... biopharmaceutical company focused on innovative oncology therapies, today announced that ... to provide a corporate overview, including a discussion about the ... at two upcoming investor conferences: , , ...
... half in study of Finnish men , WEDNESDAY, July 29 ... high-intensity exercise appears to reduce the risk of cancer, a ... men, aged 42 to 61, whose leisure-time physical activity was ... history of cancer, according to the report published online July ...
Cached Medicine News:Health News:Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors 2Health News:Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors 3Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 3Health News:Hillenbrand Announces Third-Quarter Earnings Release Date and Conference Call 2Health News:Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference 2Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches....
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches....
Medicine Products: